Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.45 |
| ▸ | LOX | P28300 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | BAX | Q07812 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8217612 | 0.86 | SMN1; SMN2 (0.71) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL22315230 | 0.81 | LTA4H (0.47) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL10055730 | 0.81 | ALDH1A1 (0.45) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL12825399 | 0.77 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL8109214 | 0.77 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL557685 | 0.77 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL753276 | 0.77 | SMN1; SMN2 (0.61) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL191210 | 0.77 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL22063717 | 0.76 | SMN1; SMN2 (1.00) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL25924369 | 0.74 | SMN1; SMN2 (0.62) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0662477-A1 | Heterobicyclic compounds with fungicidal activity | ISAGRO S.p.A. (IT) | 1995-07-12 | — | — | EP | claimed |
| CN-101522642-B | Process for preparing 6-phen0xypyrimidin-4-ol derivatives in the presence of a quinuclidine or a n-methyl pyrrolidine derivative | SYNGENTA LTD | 2013-02-06 | — | — | CN | disclosed |
| CN-101522642-B | Process for preparing 6-phen0xypyrimidin-4-ol derivatives in the presence of a quinuclidine or a n-methyl pyrrolidine derivative | SYNGENTA LTD | 2013-02-06 | — | — | CN | disclosed |
| US-8350025-B2 | Process for preparing 6-phenoxypyrimidin-4-OL derivatives in the presence of a quinuclidine or a N-methyl pyrrolidine derivatives | SYNGENTA LIMITED (GB) | 2013-01-08 | — | — | US | disclosed |
| CN-101522642-A | Process for preparing 6-phen0xypyrimidin-4-ol derivatives in the presence of a quinuclidine or a n-methyl pyrrolidine derivative | SYNGENTA LTD (GB) | 2009-09-02 | — | — | CN | disclosed |
| CN-101522642-A | Process for preparing 6-phen0xypyrimidin-4-ol derivatives in the presence of a quinuclidine or a n-methyl pyrrolidine derivative | SYNGENTA LTD (GB) | 2009-09-02 | — | — | CN | disclosed |
| EP-0693061-B1 | FUNGICIDAL OXAZOLYL AND OXADIAZOLYL DERIVATIVES | ZENECA LTD (GB) | 2000-11-22 | — | — | EP | disclosed |
| US-5716974-A | TREATING FUNGAL PLANT DISEASES | ISAGRO S.P.A. (IT) | 1998-02-10 | — | — | US | disclosed |
| EP-0662477-A1 | Heterobicyclic compounds with fungicidal activity | ISAGRO S.p.A. (IT) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994022844-A1 | FUNGICIDAL OXAZOLYL AND OXADIAZOLYL DERIVATIVES | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |